Ipca Laboratories reported 21.31% increase in consolidated net profit of Rs 233.31 crore in Q1 FY26 as against Rs 192.24 crore posted in Q1 FY25.
Revenue from operations jumped 10.33% year on year to Rs 2,308.85 crore in the quarter ended 30 June 2025.
Profit before tax (PBT) increased 13.81% to Rs 330.51 crore in Q1 FY25, compared with Rs 290.39 crore in Q1 FY25.
EBITDA stood at Rs 424.58 crore in Q1 FY26, registering the growth of 10%, compared with Rs 387.49 crore in Q1 FY25. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) stood at 18.39% in Q1 FY26 as against at 18.52% in Q1 FY25.
During the quarter, total formulations were at Rs 1,410.62 crore, up 11% YoY. Domestic business stood at Rs 961.01 crore (up 10% YoY).
Also Read
 "Union Minister Nirmala Sitharaman")
 "The year was a mixed bag for the real estate industry as housing supply slowed down but record investments came in. Industry experts believe that demand will stabilise as sales are likely to be lower compared to 2023.")
 "BSE, NSE, Indian share market, Stock market")
 "Uddhav Thackeray, Uddhav, Thackeray")
 "Yasin Malik")
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.
Shares of Ipca Laboratories fell 3.62% to Rs 1,334.40 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
